| Literature DB >> 32734251 |
Tanya S Johns1, Denver D Brown1, Alain H Litwin2,3, Georgette Goldson4, Rupinder S Buttar1, Jacqueline Kreimerman1, Yungtai Lo1, Kimberly J Reidy1, Laurie Bauman1, Frederick Kaskel1, Michal L Melamed1.
Abstract
RATIONALE &Entities:
Keywords: Chronic kidney disease; adolescents; clinical trial; group-based care; hypertension
Year: 2020 PMID: 32734251 PMCID: PMC7380347 DOI: 10.1016/j.xkme.2020.01.013
Source DB: PubMed Journal: Kidney Med ISSN: 2590-0595
Figure 1Study flow chart. Abbreviations: IQR, interquartile range; pts, patients.
Baseline Characteristics of Adult Participants
| Characteristic | All Participants (N = 50) | Group-Based Care (n = 26) | Usual Care (n = 24) |
|---|---|---|---|
| Age, y | 62 ± 11 | 63 ± 11 | 60 ± 10 |
| Female sex | 27 (54%) | 12 (46%) | 15 (62%) |
| Race/ethnicity | |||
| Non-Hispanic black | 24 (48%) | 14 (54%) | 10 (42%) |
| Non-Hispanic white | 2 (4%) | 0 (0%) | 2 (8%) |
| Hispanic | 23 (46%) | 11 (42%) | 12 (50%) |
| Other | 1 (2%) | 1 (4%) | 0 (0%) |
| High school graduate | 31 (62%) | 18 (69%) | 13 (54%) |
| Income < $15,000 per y | 20 (40%) | 11 (42%) | 9 (37%) |
| REALM score | 65 [54-66] | 65 [58-66] | 64 [53-65] |
| REALM score < 61 | 17 (36%) | 8 (32%) | 9 (41%) |
| Comorbid conditions | |||
| Diabetes mellitus | 26 (52%) | 10 (38%) | 16 (66%) |
| Coronary artery disease | 14 (28%) | 7 (27%) | 7 (29%) |
| Congestive heart failure | 9 (18%) | 2 (8%) | 7 (29%) |
| Peripheral vascular disease | 13 (26%) | 6 (23%) | 7 (29%) |
| Cerebrovascular disease | 13 (26%) | 6 (23%) | 7 (29%) |
| ACE inhibitor or ARB use | 27 (54%) | 16 (61%) | 11 (46%) |
| Diuretic use | 24 (48%) | 13 (50%) | 11 (46%) |
| β-Blocker use | 28 (56%) | 15 (58%) | 13 (54%) |
| Calcium channel blocker use | 33 (66%) | 17 (65%) | 16 (67%) |
| ≥3 antihypertensives | 27 (54%) | 16 (61%) | 11 (46%) |
| Medication nonadherence | 16 (32%) | 10 (38%) | 6 (25%) |
| Weight, kg | 95 [76-104] | 95 [80-107] | 92 [73-102] |
| BMI ≥ 30 kg/m2 | 34 (68%) | 18 (69%) | 16 (67%) |
| Current smoker | 2 (4%) | 1 (4%) | 1 (4%) |
| 24-h SBP, mm Hg | 137 ± 20 | 137 ± 18 | 137 ± 23 |
| 24-h DBP, mm Hg | 77 ± 11 | 76 ± 10 | 78 ± 12 |
| 24-h SBP ≥ 140 mm Hg | 19 (42%) | 10 (42%) | 9 (43%) |
| Office SBP, mm Hg | 139 ± 19 | 141 ± 20 | 136 ± 17 |
| Office DBP, mm Hg | 76 ± 11 | 76 ± 11 | 75 ± 12 |
| Office SBP ≥ 140 mm Hg | 24 (48%) | 11 (42%) | 13 (54%) |
| eGFR, | 35.4 ± 13.2 | 37.1 ± 12.9 | 33.6 ± 13.5 |
| 24-h sodium excretion, mg | 2,622 [1,840-3,910] | 2,599 [2,392-3,381] | 3,381 [1,840-4,416] |
Note: Values for categorical variables are given as count (proportion); values for continuous variables are given as mean ± standard deviation for normally distributed variables or median [interquartile range] for skewed variables. There were no significant differences (P > 0.05) between the groups for all measured baseline characteristics.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II type 1 receptor antagonist; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; REALM, Rapid Estimate of Adult Literacy in Medicine; SBP, systolic blood pressure.
Three patients (1 from group-based care and 2 from usual care) were unable to perform a REALM score assessment because they were legally blind. REALM score < 61 corresponds to less than high school literacy.
Data available for 24 (92%) group-based care patients and 21 (87%) usual-care patients.
eGFR was calculated using Chronic Kidney Disease Epidemiology Collaboration equation.
Data available for 17 (65%) group-based care patients and 15 (62%) usual-care patients.
Intention-to-Treat Analysis of Clinical Outcomes in Adults
| Outcome | Group-Based Care | Usual Care | Effect of Intervention Adjusted for Baseline (95% CI) | ||
|---|---|---|---|---|---|
| Baseline | 6 mo | Baseline | 6 mo | ||
| Blood pressure | |||||
| 24-h SBP, mm Hg | 139 ± 4.5 | 139 ± 3.1 | 139 ± 4.9 | 144 ± 4.0 | −4.2 (−13.8 to 5.3) |
| 24-h DBP, mm Hg | 75 ± 2.9 | 75 ± 2.1 | 78 ± 2.6 | 78 ± 3.0 | −0.5 (−6.6 to 5.7) |
| Medication nonadherence | 8 (38%) | 10 (43%) | 6 (30%) | 8 (40%) | 1.11 (0.3 to 3.9) |
| Sodium intake | |||||
| 24-h sodium excretion, mg | 2,852 ± 851 | 2,553 ± 483 | 2,783 ± 552 | 2,461 ± 598 | NE |
| FFQ, mg/d | 2,844 ± 344 | 2,600 ± 347 | 2,312 ± 365 | 2,383 ± 401 | −133 (−1,045 to 780) |
| Physical activity | |||||
| Mean steps/h | 314 ± 75 | 306 ± 59 | 223 ± 33 | 224 ± 40 | 9.3 (−50 to 69) |
| Quality of life (SF-36) | |||||
| Composite physical score | 39 ± 1.8 | 36 ± 1.6 | 37 ± 2.0 | 36 ± 2.2 | −0.7 (−4.1 to 2.6) |
| Composite mental score | 45 ± 2.1 | 47 ± 2.0 | 49 ± 2.3 | 47 ± 2.6 | 3.1 (−1.2 to 7.5) |
Note: Values are given as mean ± standard error of the mean for continuous variables; number and proportion (percent) for binary outcome.
Abbreviations: CI, confidence interval; DBP, diastolic blood pressure; FFQ, food frequency questionnaire; NE, not estimated; SBP, systolic blood pressure; SF-36, 36-Item Short Form Health Survey.
A total of 28 participants completed a 24-hour SBP and 24-hour DBP at baseline and 6 months.
A total of 43 participants completed a medication adherence assessment at baseline and 6 months.
Odds ratio for reporting nonadherence.
A total of 13 participants completed a 24-hour collection for urinary sodium excretion at baseline and 6 months.
Effect not estimated due to small number of participants with 24-hour urine collection at baseline and 6 months.
A total of 43 participants completed FFQs at baseline and 6 months.
A total of 33 participants completed accelerometer testing at baseline and 6 months.
A total of 43 participants completed the SF-36 at baseline and 6 months.
Baseline Characteristics of Adolescent Participants
| Patient Characteristics | All Participants (N = 10) |
|---|---|
| Mean age, y | 18 [16-19] |
| Male sex | 8 (80%) |
| Race/ethnicity | |
| Non-Hispanic black | 4 (40%) |
| Hispanic | 6 (60%) |
| Mean neighborhood income | $35,217 |
| REALM score | 64 [64-66] |
| Comorbid conditions | |
| Diabetes | 2 (20%) |
| ACE inhibitor or ARB use | 5 (50%) |
| Diuretic use | 1 (10%) |
| Calcium channel blocker use | 1 (10%) |
| β-Blocker use | 0 (0%) |
| Receiving >1 antihypertensives | 0 (0%) |
| Weight, kg | 84 [74-112] |
| eGFR, | 91.2 ± 25.6 |
| BMI ≥ 30 kg/m2 | 5 (50%) |
| 24-h SBP, mm Hg | 133 ± 4 |
| 24-hour DBP, mm Hg | 75 ± 5 |
| Office SBP, mm Hg | 127 ± 8 |
| Office DBP, mm Hg | 76 ± 10 |
| 24-h sodium excretion, mg | 3,701 [2,713-6,092] |
Note: Values for categorical variables are given as count (proportion); values for continuous variables are given as mean ± standard deviation for normally distributed variables or median [interquartile range] for skewed variables.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II type 1 receptor antagonist; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; REALM, Rapid Estimate of Adult Literacy in Medicine; SBP, systolic blood pressure.
Seven individuals were age appropriate for the REALM tool.
REALM scores normalized to general population.
eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation for adolescents aged 18 to 21 years and the bedside Schwartz equation for adolescents aged 12 to 17 yers.
Complete data available except for the following variables: d6 individuals had mean 24-hour ambulatory SBP and DBP at baseline and e6 individuals had urine sodium values at baseline.
Clinical Outcomes for the Adolescents Cohort
| Outcome | Group-Based Care | |
|---|---|---|
| Baseline | 6 mo | |
| Blood pressure | ||
| Office SBP, mm Hg | 127 ± 8 | 125 ± 10 |
| Office DBP, mm Hg | 76 ± 10 | 78 ± 8 |
| Medication nonadherence | 4 (57%) | 2 (40)% |
| Sodium intake | ||
| 24-hr sodium excretion, mg | 3,701 [2,713-6,092] | 3,816 [3,724-4,345] |
| FFQ, mg/d | 3,878 ± 1,760 | 3075 ± 2,303 |
| Physical activity | ||
| Mean steps/h | 499 [111-712] | 688 [302-1,107] |
| Psychosocial (PedsQL) | ||
| Physical functioning | 94 ± 8.5 | 93 ± 6.4 |
| Emotional functioning | 84 ± 15.9 | 93 ± 7.6 |
| Social functioning | 100 ± 0 | 100 ± 0 |
| School functioning | 81 ± 15.6 | 80 ± 8.7 |
Note: Values for continuous variables are given as mean ± standard deviation for normally distributed variables and median [interquartile range] for non-normally distributed variables.
Abbreviations: DBP, diastolic blood pressure; FFQ, food frequency questionnaire; PedQL, Pediatric Quality of Life Inventory; SBP, systolic blood pressure.
A total of 6 participants had an office SBP and DBP at baseline and 6 months.
A total of 5 participants completed the nonadherence question at baseline and 6 months.
A total of 3 participants completed 24-hour urinary sodium excretion at baseline and 6 months.
A total of 5 participants completed the FFQ at baseline and 6 months.
A total of 5 participants completed the accelerometer testing at baseline and 6 months.
A total of 3 participants completed the PedsQL scale at baseline and 6 months.